The Role of Genomics in Outbreak Investigations

Prameet M. Sheth MSc. PhD. D(ABMM), F(CCM) Director, Molecular Microbiology and Infectious Disease Sequencing Division of Microbiology, Kingston Health Sciences Centre

> Associate Professor Department of Pathology and Molecular Medicine Gastrointestinal Disease Research Unit (GIDRU) Queen's University, Kingston, ON.

> > Hosted by Martin Kiernan martin@webbertraining.com

www.webbertraining.com

December 14, 2023



 Member of the Strategic committee for the Ontario COVID-19 Genomics Network (OCGN).

"If I have seen further, it is by standing on the shoulders of giant" - Sir Issac Newton

KHSC Microbiology Lab

Hasan Alam Shari Batson Meghan Breen Cecilia Cachaco **Ron Clare** Madalyn Derring **Beth Dermott** JoAnn Dupuis Melissa Forman Sarah Funnell Ashlee Harper **Emily Hartjes Erin Headrick** Kalyna Heffernan Rebecca Kooi Jeremy Koscik, Will Kotyk, Ron Lactam. Martha Ledford, Marie Cloutier-Lachance

Brittaney Martin Natasha Reid Kelsey Van Zeggelaar Julia Smith Rebecca Loewen Rowan MacLean

Infectious Disease Sequencing Labs

Nick Buchner Phung Ta Drew Robertson Jacob Whalen Sheri Levesque

Leadership

Sherri Wilson Dr. Henry Wong Dr. Calvin Sjaarda Dr. Lewis Tomalty Sheri Levesque Diane Ryan Jeremy Wilson

KHSC IPAC

Natasha Salt Dr. Gerald Evans Heather Candon Trisha Raney Sean Bradley Lisa Hope Emily Moslinger Megan Oliveria Wendy Benn-Abrams Ian Kudryk Ashley McGinn Nicholas Scholey

Collaborators

Dr. Samir Patel Dr. Allison McGeer Dr. Kevin Schwartz Dr. Hugh Guan Dr. Robert Kozak Dr. Ramzi Fattouh Dr. Danielle Brabant-Kirwan Dr. Finlay MacGuire Dr. Jennifer Guthrie Dr. Santiago Parez Patrigeon

Learning Objectives.


 Summarize the different genomic assays used in "genomics".

 Recognize methods used to distinguish organisms at the species/strain level.


Apply knowledge of the principles of health and disease surveillance.

 Assess different methods to distinguish disease clusters and the limitations of genomic typing.

Taxonomic Differentiation of Organisms.




PCR Amplification.




- Inexpensive (\$), limited computing power required (*)
- Require expertise for molecular assays less of an issue now post COVID-19.
- Need to know your target(s) ahead of time.

Pulse-Field Gel Electrophoresis



- Only be used for Bacteria and/or Fungi.
- Labor Intensive and require laboratory space.
- Limited number of samples can be interrogated at one time.
- Limited resolution unclear what the changes were and how to assign them.

Multilocus Sequence Typing (MLST)



• Distinguished organisms base on highly conserved "house-keeping genes".


• Look for changes in house keeping genes to determine strain level difference.

• Cheap (\$\$) but significant human resources required.

• Isolates need to be cultured and need to know what to look for.


• Different organisms have different levels of 'basal" mutations in house keeping genes.

The Changing Landscape of Genomics.




Human Genome Project - 12 donors, Sequenced 90% of the human genome - \$3 Billion. — Today's cost for 12 donor genomes - \$12,000

Amplicon Based Sequencing (NGS)



"Shot-gun" Sequencing



Does not require prior knowledge of what to look for, can be used for new pathogens.
(pathogen discovery)

• Expensive (\$\$\$\$).

 Significant computing power required (****).


• Significant expertise in bioinformatics required (****).

For now...rarely used in a clinical setting.


Communicable Disease Transmission.




Contact Tracing




Digital and Analog Contact Tracing




The Incubation Period.



Challenges with Contact Tracing






The higher the Ro, the greater need for better contact tracing.

But once the Ro is > 3 - the efficacy of contact tracing is close to 0% - at least according to this model in a community setting.


Genomic Community Surveillance

Amplicon-based Sequencing



Base Mutation rate

F



Sjaarda and Sheth et al, mSphere 2021




Genomics based epidemiology.

scientific reports

OPEN Phylogenomics reveals viral sources, transmission, and potential superinfection in early-stage COVID-19 patients in Ontario, Canada


www.nature.com/scientificreports

Calvin P. Sjaarda^{1,28}, Nazneen Rustom^{2,3}, Gerald A. Evans^{5,56}, David Huang⁷, Santiago Perez-Patrigoon⁵, Melissa L. Hudson^{1,2}, Henry Wong⁹, Zhengxin Sun⁷, T. Hugh Guan⁹, Muhammad Ayub^{2,3}, Claudio N. Soares^{1,2}, Robert I. Colautti^{7,11} & Prameet M. Sheth^{5,68,19,11}



- Introduction of 2 distinct lineages of the SARS-CoV-2 virus into Eastern Ontario.
- Lineage A Directly from Wuhan
- Lineage B Multiple Variants from Europe, UK and the US.
- Blinded genomics analysis and contact tracing done by separate team members.

Viral phylogeny and Prevalence of SARS-CoV-2 strains in Eastern Ontario.



Monitoring Emerging Variants of Concern.

-	RUN_ID 🗧	Unique_ID	LINEAGE_old [‡]	LINEAGE ¢	SAMPLE_COLLECTION_DATE
1	Run329	ON-KHS-22-16700-v1	XBB.1	XBB.1.5	2022-12-11
2	Run329	ON-KHS-22-16712-v1	XBB.1	XBB.1.5	2022-12-12
3	Run329	ON-KHS-22-16718-v1	XBB.1	XBB.1.5	2022-12-12
4	Run332	ON-KHS-22-16946-v1	XBB.1	XBB.1.5	2022-12-17
5	Run335	ON-KHS-22-17170-v1	XBB.1	XBB.1.5	2022-12-24
6	Run335	ON-KHS-22-17206-v1	XBB.1	XBB.1.5	2022-12-22
7	Run335	ON-KHS-22-17222-v1	XBB.1	XBB.1.5	2022-12-23
8	Run337	ON-KHS-23-00015-v1	XBB.1.5	XBB.1.5	2022-12-28
9	Run337	ON-KHS-23-00029-v1	XBB.1.5	XBB.1.5	2022-12-29
10	Run337	ON-KHS-23-00032-v1	XBB.1.5	XBB.1.5	2022-12-29
11	Run337	ON-KHS-23-00081-v1	XBB.1.5	XBB.1.5	2022-12-29
12	Run338	ON-KHS-23-00145-v1	XBB.1.5	XBB.1.5	2022-12-29
13	Run338	ON-KHS-23-00150-v1	XBB.1.5	XBB.1.5	2022-12-29
14	Run338	ON-KHS-23-00155-v1	XBB.1.5	XBB.1.5	2022-12-29
15	Run338	ON-KHS-23-00166-v1	XBB.1.5	XBB.1.5	2022-12-30

• Allows for continuous surveillance for new and emerging variants of concern.

• Changes in epidemiology.




How Different is Different Enough?

Best of a Bad Method: Optimal use of SNP distance thresholds for SARS-CoV-2 transmission clustering

Peter C. Jentsch^{1,2}, Calvin P. Sjaarda^{3,4}, Jennifer L. Guthrie^{5,6}, Robert A. Kozak^{1,7}, Chris Kandel^{7,9}, Prameet M. Sheth^{3,4}, Henry Wong^{3,4}, Allison McGeer^{7,9}, Samira Mubareka^{1,7}, and Finlay Maguire^{1,8}


> ¹Sunnybrook Research Institute, Toronto, Canada ²Simon Fraser University, Burnaby, Canada ³Queen's University, Kingston, Canada ⁴Kingston Health Sciences Centre, Kingston, Canada ⁵Western University, London, Canada ⁶Public Health Ontario, Toronto, Canada ⁷University of Toronto, Toronto, Canada ⁸Dalhousie University, Halifax, Canada ⁹Mount Sinai Hospital, Toronto, Canada



 Used 15,504 sequences from KHSC from the beginning of the pandemic to the Omicron BA.2 lineage (Included Alpha, Delta, Omicron).

 636 outbreak clusters from 1395 patients.

How Different is Different Enough?



 Using 2 nucleotide change as a threshold had a sensitivity of >80% for Alpha/Gamma but < 60% of Delta and Omicron isolates

 Using 3 nucleotide differences allow us to differentiate between viruses within a set time with an accuracy of >90% for all the VOC variants.

 So for our outbreak reports we chose to use 3 SNP's to call out a virus as being "different". Challenges / Limitation of using Genomics in Institutional Outbreaks.

Require infrastructure and personnel


Timeliness - takes ~ 4 - 7 days from sample collection.

 Need to establish a threshold for calling a strain 'related' vs. 'unrelated'.

 Cannot determine direction of transmission. mutations are not acquired in one direction.

Genomics for Outbreak Management

SARS-CoV-2 Genomics



27

Genomic Informed Outbreak Investigations - SARS-CoV-2

- 19 person outbreak at KHSC.
 Patients and staff involved.
- Time and place analysis suggested all of the patients were part of one outbreak cluster.
- Genomics verified that the viruses were almost identical in all of the individuals.
- Evaluate what changes can be made to mitigate further spread and transmission.






Figure 1. Phylogenetic shows how samples are related to each other based on viral genome sequencing.





Genomic Informed Outbreak Investigations - SARS-CoV-2.





Figure 1. Phylogenetic shows how samples are related to each other based on viral genome sequencing.





- 10 person outbreak at KHSC time and place analysis suggested that all the cases were "related".
- The IPAC team called an outbreak and started investigating a break down in process / protocol.
- Genomics revealed that there were 4 - distinct viruses circulating amongst the 10 people involved.
- led to significant anxiety amongst the staff on the floor.

Outbreak Reports to IPAC

Kingston Health Sciences Centre

SARS-CoV-2 Outbreak Whole Genome Sequencing Report

Introduction

Outbreaks in health care or institutional settings are particularly challenging as infection prevention and control, occupational health and safety, and public health must quickly investigate, assess, isolate infected cases and trace potential exposures to mitigate further spread of the pathogen within the facility. Time-resolved SARS-CoV-2 whole genome sequencing can facilitate a deeper understanding of the dynamics of localized spread of SARS-CoV-2 to aid organizations understand and control the outbreak dynamics.

Reports Overview

In-depth genomic analysis can be performed in cases where the PHU, hospital, or organization is investigating the outbreak for specimen relatedness to assess the possibility of multiple introductions, nosocomial transmission, etc.

Sample Prerequisites

Specimen Eligibility

- 1. Specimen Volume: 1ml (0.5 ml as absolute minimum)
- 2. Ct \leq 30 from the e-gene PCR test

Outbreak Reports.

31 person outbreak at KHSC – 23 patients – one cluster.

	ON-KHS-22-13939-v1 ON-KHS-22-13147-v1	T	Tabla	2 Lineage and gamen	aa accienment fe		ith outbrook	Ŀ	
Outbreak Number	ON-KHS-22-13954-v1 ON-KHS-22-13955-v1		Case	2. Lineage and genon NGS No	Genome Completeness	Pango Lineage (WHO label)	Cluster	K Loc	Outbreak Number
Outbreak Number	ON-KHS-22-13146-v1		1	ON-KHS-22-12723-v1	0.9865	BA.5.2 (Omicron)	V	S 3	2241-2022-68808
• 2241-2022-68808	ON-KHS-22-13005-v1		2	ON-KHS-22-12911-v1	0.9887	BA.5.2 (Omicron)	V	S3	2241-2022-68808
2241-2022-69307			3	ON-KHS-22-13005-v1	0.9786	BA.5.2 (Omicron)	V	S3	2241-2022-68808
	ON-KHS-22-12723-v1		4	ON-KHS-22-13068-v1	0.9955	BA.5.2 (Omicron)	V	S 3	2241-2022-68808
2241-2022-69560	ON-KHS-22-12911-v1		5	ON-KHS-22-13069-v1	0.9928	BA.5.2 (Omicron)	V	S3	2241-2022-68808
• 2241-2022-69717	ON-KHS-22-13069-v1		6	ON-KHS-22-13140-v1	0.9931	BA.5.2 (Omicron)	V	S3	2241-2022-68808
	ON-KHS-22-13952-v1		7	ON-KHS-22-13144-v1	0.9958	BA.5.2 (Omicron)	V	S3	2241-2022-68808
	ON-KHS-22-13756-v1		8	ON-KHS-22-13145-v1	0.9774	BA.5.2 (Omicron)	V	S3	2241-2022-68808
	ON-KHS-22-13780-v1	Cluster V	9	ON-KHS-22-13146-v1	0.9873	BA.5.2 (Omicron)	v	S3	2241-2022-68808
		Cluster v	10	ON-KHS-22-13147-v1	0.9286	BA.5.2 (Omicron)	v	S3	2241-2022-68808
	• ON-KHS-22-14044-v1		11	ON-KHS-22-13283-v1	0.9359	BA.5.2 (Omicron)	V	S 3	2241-2022-68808
	ON-KHS-22-13144-v1		13	ON-KHS-22-13452-v1	0.8420	BA.5.2 (Omicron)	V	S3	2241-2022-68808
	ON-KHS-22-13068-v1		12	ON-KHS-22-13376-v1	0.9446	BF.5 (Omicron)	W	S4	2241-2022-69307
	ON-KHS-22-13140-v1		14	ON-KHS-22-13645-v1	0.7581	BF.5 (Omicron)	w	S4	2241-2022-69307
	ON-KHS-22-13971-v1		16	ON-KHS-22-13748-v1	0.9475	BE.1.2.1 (Omicron)	Z	S4	2241-2022-69307
	ON-KHS-22-13959-v1		18	ON-KHS-22-13767-v1	0.9596	BF.5 (Omicron)	W	S4	2241-2022-69307
	ON-KHS-22-13145-v1		19	ON-KHS-22-13777-v1	0.9587	BE.1.2.1 (Omicron)	Z	S4	2241-2022-69307
			32	ON-KHS-22-14043-v1	0.9929	BF.5 (Omicron)	W	S4	2241-2022-69307
	ON-KHS-22-13452-v1		15	ON-KHS-22-13655-v1	0.9385	BA.5.2.1 (Omicron)	Y	S5	2241-2022-69560
	ON-KHS-22-13956-v1		20	ON-KHS-22-13780-v1	0.9289	BA.5.2.6 (Omicron)	v	S5	2241-2022-69560
	ON-KHS-22-13960-v1		24	ON-KHS-22-13954-v1	0.9796	BA.5.2 (Omicron)	v	S5	2241-2022-69560
	ON-KHS-22-13283-v1		25	ON-KHS-22-13955-v1	0.9851	BA.5.2 (Omicron)	V	S5	2241-2022-69560
	• ON-KHS-22-13645-v1		26	ON-KHS-22-13956-v1	0.9744	BA.5.2 (Omicron)	v	S5	2241-2022-69560
	ON-KHS-22-13767-v1		27	ON-KHS-22-13957-v1	0.2569	FAILED		S5	2241-2022-69560
		Cluster W	28	ON-KHS-22-13958-v1	0.9000	BA.5.2.1 (Omicron)	x	S5	2241-2022-69560
	ON-KHS-22-14043-v1	1	29	ON-KHS-22-13959-v1	0.9142	BA.5.2 (Omicron)	v	S5	2241-2022-69560
	ON-KHS-22-13376-v1		30	ON-KHS-22-13960-v1	0.9508	BA.5.2 (Omicron)	v	S5	2241-2022-69560
	ON-KHS-22-13958-v1	Cluster X	31	ON-KHS-22-13971-v1	0.9874	BA.5.2 (Omicron)	V	S5	2241-2022-69560
	Ч¬¬•ON-КНS-22-13655-v1	Cluster Y	17	ON-KHS-22-13756-v1	0.9438	BA.5.2.6 (Omicron)	v	M4	2241-2022-69717
	• ON-KHS-22-13748-v1		21	ON-KHS-22-13939-v1	0.9676	BA.5.2 (Omicron)	V	M4	2241-2022-69717
	ON-KHS-22-13777-v1	Cluster Z	22	ON-KHS-22-13952-v1 ON-KHS-22-13953-v1	0.9938 0.0264	BA.5.2 (Omicron)	V	M4	2241-2022-69717
			23	ON-KHS-22-13953-V1 ON-KHS-22-14044-v1	0.0264	FAILED BA.5.2 (Omicron)	v	M4 M4	2241-2022-69717
	Reference			: 'FAILED' includes sam					2241-2022-69717
0.000	0.001 0.002	0.003		정말 - 영상의 대학교 가격 전화 - 영향적 수상 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등					
1 Phylogopotic chows ha	w complete are related to each other based on viral		refers	to a group of SARS-Co	/-2 sequences that	at are genetically relat	ed (≥3 mutat	ions). Genor	me designations

Figure 1. Phylogenetic shows how samples are related to each other based on viral genome sequencing.

r re arbitrary letters assigned to delineate genomes containing related sequences and are specific to this WGS request.

Amplicon-based Sequencing for Mpox

Canada-EPI_ISL_13544227 Canada-EPI ISL 13544223 KHSC_MkpV_barcode08 Canada-EPI_ISL_13544224 Canada-EPI_ISL_13544233 Canada-EPI ISL 13544231 Canada-EPI_ISL_13827278 Canada-EPI_ISL_14050455 Canada-EPI_ISL_13408845 Canada-EPI ISL 13408805 Clade Canada-EPI ISL 13544249 IIb A.1 Canada-EPI_ISL_13408821 IIb A.2 Canada-EPI_ISL_13544228 IIb B.1 Canada-EPI ISL 13544243 IIb B.1.4 Canada-EPI ISL 13408827 Canada-EPI ISL 14050456 Canada-EPI_ISL_14487650 Canada-EPI ISL 14050451 Canada-EPI ISL 14050453 Canada-EPI_ISL_13408839 KHSC_MkpV_barcode07 cvno USA_EPI ISL 13094227

MT903345

- •Two-patients tested positive for Mpox in the community.
- •Health unit was contact tracing to determine community transmission.
- Genomics identified that the strains were very different.
 - Allowed us to inform our health unit sure that this was not community transmission.


Sjaarda and Sheth, Journal of Infectious Diseases 2023

Monitoring Anti-Viral Resistance to SARS-CoV-2

- Nirmatrelvir-ritonovir (Paxlovid) is a newly developed protease inhibitor that is the leading antiviral drug against SARS-CoV-2.
- Paxlovid is an oral drug that is taken twice daily for 5 days in non-hospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression.
- Short dose duration of Paxlovid, is resistance really an issue??

Sjaarda, Wong and Sheth et al, JAMA Network Open 2023

Lessons from the Past : Influenza and Amantadine



Amantadine was a drug used against Influenza A.

Amantadine was administered within 24 -48 hours after symptom onset and continued for 24 to 48 hours after symptom resolution.

Short dose, resistance developed rapidly...drug is no longer indicated for Influenza A.

Monitoring Anti-Viral Resistance to SARS-CoV-2

Network Open...

Original Investigation | Infectious Diseases

Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-2023

Calvin P. Sjaarda, PhD; Lynette Lau, MSc; Jared T. Simpson, PhD; Ramzi Fattouh, PhD; Mia J. Biondi, PhD, NP-PHC; Finlay Maguire, PhD; Aaron Campigotto, MD, MSc; Yujia Feng; Kyla Tozer, BHSc; Henry Wong, PhD; Wilson W. L. Sung, MSc; Sean Kim, BSc; Christian R. Marshall, PhD; Prameet M. Sheth, MSc, PhD, D(ABMM); Robert Kozak, PhD

Abstract

IMPORTANCE Nirmatrelvir-ritonavir is an oral antiviral medication that improves outcomes in SARS-CoV-2 infections. However, there is concern that antiviral resistance will develop and that these viruses could be selected for after treatment.

OBJECTIVE To determine the prevalence of low-frequency SARS-CoV-2 variants in patient samples that could be selected for by nirmatrelvir-ritonavir.

DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study was conducted at 4 laboratories that serve community hospitals, academic tertiary care centers, and COVID-19 assessment centers in Ontario, Canada. Participants included symptomatic or asymptomatic patients who tested positive for SARS-CoV-2 virus and submitted virus samples for diagnostic testing between March 2020 and January 2023.

EXPOSURE SARS-CoV-2 infection.

MAIN OUTCOMES AND MEASURES Samples with sufficient viral load underwent next-generation genome sequencing to identify low-frequency antiviral resistance variants that could not be identified through conventional sequencing.

RESULTS This study included 78 866 clinical samples with next-generation whole-genome sequencing data for SARS-CoV-2. Low-frequency variants in the viral *nsp5* gene were identified in 128 isolates (0.16%), and no single variant associated with antiviral resistance was predominate.

CONCLUSIONS AND RELEVANCE This cohort study of low-frequency variants resistant to nirmatrelvir-ritonavir found that these variants were very rare in samples from patients with SARS-CoV-2, suggesting that selection of these variants by nirmatrelvir-ritonavir following the initiation of treatment may also be rare. Surveillance efforts that involve sequencing of viral isolates should continue to monitor for novel resistance variants as nirmatrelvir-ritonavir is used more broadly.

JAMA Network Open. 2023;6(7):e2324963. doi:10.1001/jamanetworkopen.2023.24963

Key Points

Question What is the prevalence of low-frequency variants in SARS-CoV-2 isolates from patient samples that could confer resistance to nirmatrelvirritonavir?

Findings In this cohort study, 78 866 SARS-CoV-2 isolates from patients underwent next-generation sequencing, and low-frequency variants were detected in 128 samples (0.16%).

Meaning These findings suggest that SARS-CoV-2 variants that could be selected for by treatment with nirmatrelvir-ritonavir are rare and that surveillance efforts that involve sequencing of viral isolates should continue to monitor for novel resistance variants.

+ Supplemental content


Author affiliations and article information are listed at the end of this article.


- We evaluated >78,000 SARS-CoV-2 sequences from patients in Ontario, Canada between March 2000 and Jan 2023.
- Paxlovid resistance was found in 128/78,866 (0.16%) of clinical isolates.
- Levels of resistance were evaluated using the genomic sequences from the Ontario COVID-19 genomics laboratories led by Dr. Kozak (Toronto) and Dr. Sheth (Eastern and Northern Ontario).

 Currently doing a follow up study with over 100,000 patients and using provincial data to monitor Paxlovid Resistance.

Sjaarda, Wong and Sheth et al, JAMA Network Open 2023

Combining Genomics and Patient Outcomes





The Borg were wrong !!

RESISTANCE IS NOT FUTILE

....IT IS INEVITABLE

Wong, Sjaarda and Sheth, Unpublished data

Summary

- Genomics is very useful for population level surveillance for emerging and endemic pathogen.
- The wide adoption of Genomics is currently impeded by costs linked to personnel and computing.
- Analysis is challenging as it is organism dependent and need to know the stability of the genome.
- Need to incorporate genomics into outbreak investigations to help with Public Health and Institutional Contact Tracing for a wider array of pathogens (Syphilis, Influenza, C. difficile, Salmonella, Shigella, Multidrug Resistant Organisms (MDRO), TB etc).



Thank you for your time. Happy to take questions !

www.webbertraining.com/schedulep1.php				
January 11, 2024	(FREE Teleclass) DISCOURSE: HOW OUR LANGUAGE INFLUENCES OUR ATTEMPTS TO PREVENT AND CONTROL HEALTHCARE-ASSOCIATED INFECTION Speaker: Prof. Mark Cole, The University of Manchester			
January 18, 2024	THROW IT AWAY: HOW INFECTION CONTROL PRACTICE DESTROYS PLANETARY HEALTH AND FUELS LABOUR ABUSE Speaker: Prof. Mahmood Bhutta, University of Sussex			
January 25, 2024	(FREE Teleclass) ENCOUNTERING BED BUGS WHILE ON VACATION, OR JUST TRAVELLING Speaker: Dr. Marcia L. Anderson, EPA Center for Integrated Pest Management			
February 1, 2024	DEVELOPING A BETTER UNDERSTANDING OF WHY HYGIENE IS KEY TO DEVELOPING EFFECTIVE HYGIENE BEHAVIOUR IN HOMES AND EVERYDAY LIVES Speaker: Dr. Sally Bloomfield, International Scientific Forum on Home Hygiene			
February 8, 2024	TARGETED HYGIENE: A RISK-BASED APPROACH TO APPLYING POLICIES ANDHYGIENE INTERVENTIONS IN PUBLIC SETTINGS AND LARGE EVENTSSpeaker: Dr. Lisa Ackerley, International Scientific Forum on Home Hygiene			
February 14, 2024	(Australasian Teleclass) HUMAN AMR SURVEILLANCE – WHERE ARE WE NOW AND WHERE SHOULD WE BE HEADING? Speaker: Dr. Paul Turner, Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Cambodia			

Thanks to Teleclass Education **PATRON SPONSORS**







gamahealthcare.com

diversey.com

virox.com